V Square Quantitative Management LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

V Square Quantitative Management LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,221 shares of the company’s stock after selling 703 shares during the period. Johnson & Johnson accounts for 1.0% of V Square Quantitative Management LLC’s investment portfolio, making the stock its 11th biggest holding. V Square Quantitative Management LLC’s holdings in Johnson & Johnson were worth $6,171,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Investment Partners Asset Management Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $1,020,000. Financial & Tax Architects LLC boosted its holdings in Johnson & Johnson by 0.7% in the fourth quarter. Financial & Tax Architects LLC now owns 34,208 shares of the company’s stock valued at $5,362,000 after acquiring an additional 252 shares in the last quarter. Beddow Capital Management Inc. raised its holdings in Johnson & Johnson by 0.9% in the 4th quarter. Beddow Capital Management Inc. now owns 50,143 shares of the company’s stock worth $7,859,000 after purchasing an additional 425 shares in the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH lifted its position in shares of Johnson & Johnson by 0.8% in the 4th quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 27,111 shares of the company’s stock worth $4,249,000 after purchasing an additional 221 shares during the period. Finally, O Brien Wealth Partners LLC increased its position in shares of Johnson & Johnson by 14.4% during the fourth quarter. O Brien Wealth Partners LLC now owns 2,355 shares of the company’s stock valued at $369,000 after buying an additional 296 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.2 %

JNJ traded up $0.25 during trading hours on Wednesday, reaching $158.64. The company’s stock had a trading volume of 2,214,946 shares, compared to its average volume of 7,338,182. The business’s 50-day moving average is $151.63 and its 200-day moving average is $153.06. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The stock has a market cap of $381.80 billion, a PE ratio of 9.89, a P/E/G ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.39.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.13%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Morgan Stanley increased their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 5th. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Bank of America cut their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Finally, TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.